These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1881161)

  • 1. Legal requirements for the use of phytopharmaceutical drugs in the Federal Republic of Germany.
    Keller K
    J Ethnopharmacol; 1991 Apr; 32(1-3):225-9. PubMed ID: 1881161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European regulation model for herbal medicine: The assessment of the EU monograph and the safety and efficacy evaluation in marketing authorization or registration in Member States.
    Qu L; Zou W; Wang Y; Wang M
    Phytomedicine; 2018 Mar; 42():219-225. PubMed ID: 29655689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Herbal medicine products and drug law].
    Kraft K
    Forsch Komplementarmed; 1999 Feb; 6(1):19-23. PubMed ID: 10213877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-European traditional herbal medicines in Europe: a community herbal monograph perspective.
    Qu L; Zou W; Zhou Z; Zhang T; Greef J; Wang M
    J Ethnopharmacol; 2014 Oct; 156():107-14. PubMed ID: 25169214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of herbal medicines submitted for marketing authorization in Tanzania: a cross-sectional retrospective study.
    Mssusa AK; Holst L; Kagashe G; Maregesi S
    J Pharm Policy Pract; 2023 Nov; 16(1):149. PubMed ID: 37986124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies for use in man: current regulatory situation in the Federal Republic of Germany.
    Haase M
    Dev Biol Stand; 1990; 71():213-20. PubMed ID: 2205526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H; Lewicki J
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cannabis for medicinal use: development of pharmacopoeia monographs as a quality standard].
    Manns D; Norwig J; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Jul; 62(7):806-810. PubMed ID: 31139840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New European commission regulation on variations to the terms of marketing authorization for medicinal products and its impact on Croatian legislation.
    Martinac AI; Tomić S; Simicić M
    Arh Hig Rada Toksikol; 2010 Sep; 61(3):311-22. PubMed ID: 20860972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
    Dejas-Eckertz P; Schäffner G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marketing authorisation of fish drugs--current status and future intentions.
    Bernoth EM
    Zentralbl Veterinarmed B; 1990 Aug; 37(6):401-6. PubMed ID: 2402969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Allergens for specific immunotherapy: authorization and quality criteria of the Paul-Ehrlich-Institut].
    May S; Kaul S; Schröder C; Vieths S
    Hautarzt; 2006 Oct; 57(10):867-74. PubMed ID: 16977441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new European legislation on traditional herbal medicines: main features and perspectives.
    Silano M; De Vincenzi M; De Vincenzi A; Silano V
    Fitoterapia; 2004 Mar; 75(2):107-16. PubMed ID: 15030913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents).
    Calixto JB
    Braz J Med Biol Res; 2000 Feb; 33(2):179-89. PubMed ID: 10657057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.